Videos

April 17th, 2019

Silence Therapeutics accelerating into the clinic

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates Proactive London's Andrew Scott on the progress of its lead candidate SLN124 which is being developed to treat iron overload disorders.